Mark Shilkrut
Impact in
- Oncology top 10%
- CAR-T cell therapy research
- Cell Biology top 10%
- Hemoglobin structure and function
Papers in
- Oncology 23
- CAR-T cell therapy research 13
- HER2/EGFR in Cancer Research 4
-
- Melanoma and MAPK Pathways 5
- Co-authors
- Ofer Binah (12 shared papers)Naama Zeevi‐Levin (5 shared papers)Asaf Danon (4 shared papers)Katya Dolnikov (3 shared papers)Joseph Itskovitz‐Eldor (3 shared papers)Howard L. Kaufman (7 shared papers)Robert H.I. Andtbacka (6 shared papers)Sharon Gerecht‐Nir (2 shared papers)
- Journals
- Annals of Oncology (4 papers)Journal of Clinical Oncology (4 papers)Journal for ImmunoTherapy of Cancer (3 papers)Cardiovascular Research (2 papers)Circulation Research (2 papers)
- Partner nations
- United StatesIsraelAustralia
In The Last Decade
Mark Shilkrut
45 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 78
- Oncology 378
- Cell Biology 176
- Genetics 267
- Molecular Biology 648
- Immunology 189
Countries citing papers authored by Mark Shilkrut
This map shows the geographic impact of Mark Shilkrut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Shilkrut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Shilkrut more than expected).
Fields of papers citing papers by Mark Shilkrut
This network shows the impact of papers produced by Mark Shilkrut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Shilkrut. The network helps show where Mark Shilkrut may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Shilkrut, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 240 | |
| 2 | 2003 | 213 | |
| 3 | 2005 | 148 | |
| 4 | 1998 | 65 | |
| 5 | 2007 | 62 | |
| 6 | 2002 | 52 | |
| 7 | 2005 | 49 | |
| 8 | 2016 | 49 | |
| 9 | 2012 | 35 | |
| 10 | 2005 | 35 | |
| 11 | 2012 | 34 | |
| 12 | 2017 | 34 | |
| 13 | 2010 | 30 | |
| 14 | 2013 | 21 | |
| 15 | 2014 | 19 | |
| 16 | 2018 | 16 | |
| 17 | 2005 | 15 | |
| 18 | 2003 | 14 | |
| 19 | 2011 | 14 | |
| 20 | 2004 | 14 |
About Mark Shilkrut
Mark Shilkrut is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Genetics and Cardiology and Cardiovascular Medicine, having authored 45 papers that have together received 1.3k indexed citations. Recurring topics across this work include CAR-T cell therapy research (13 papers), Virus-based gene therapy research (9 papers), Cardiac electrophysiology and arrhythmias (8 papers), Cancer Research and Treatments (6 papers), Melanoma and MAPK Pathways (5 papers), Prostate Cancer Treatment and Research (5 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and HER2/EGFR in Cancer Research (4 papers). The work is most often cited by research in Oncology (378 citations), Cell Biology (176 citations), Genetics (267 citations), Molecular Biology (648 citations) and Immunology (189 citations). Mark Shilkrut has collaborated with scholars based in United States, Israel and Australia. Frequent co-authors include Ofer Binah, Naama Zeevi‐Levin, Asaf Danon, Katya Dolnikov, Joseph Itskovitz‐Eldor, Howard L. Kaufman, Robert H.I. Andtbacka, Sharon Gerecht‐Nir, Thomas Amatruda and Michal Amit. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Cardiovascular Research and Circulation Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.